Number of Participants with Adverse Events of Special Interest (AESIs);Number of Participants with AEs Leading to Discontinuation;Number of Participants with Medically-Attended AEs (MAAEs);Number of Participants with Serious Adverse Events (SAEs);Number of Participants with Solicited Local and Systemic Adverse Reactions (ARs);Number of Participants with Unsolicited Adverse Events (AEs)

Number of Participants with Adverse Events of Special Interest (AESIs);Number of Participants with AEs Leading to Discontinuation;Number of Participants with Medically-Attended AEs (MAAEs);Number of Participants with Serious Adverse Events (SAEs);Number of Participants with Solicited Local and Systemic Adverse Reactions (ARs);Number of Participants with Unsolicited Adverse Events (AEs)